HLA-G and neoplasm: HLA-G expression in tumor cells has been identified as another mediator of trastuzumab resistance, which, when coupled to the HLA-G/KIR2DL4 interaction, enhances the vulnerability of HER2+ breast tumors to trastuzumab treatment in vivo [105].